Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884740 | 0.86 | STAT3 (1.00) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL13980997 | 0.85 | STAT3 (0.76) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL10165364 | 0.82 | STAT3 (0.72) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL10203639 | 0.82 | STAT3 (0.72) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL26694396 | 0.81 | POLB (0.71) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL1796529 | 0.81 | STAT3 (0.50) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL2187853 | 0.79 | STAT3 (0.67) | STAT3POLBMAPTALDH1A1KMT2A | |
| SCHEMBL28512724 | 0.78 | IDO1 (0.60) | STAT3ALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8531486 | 0.76 | IDO1 (0.58) | STAT3MAPTALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL8531490 | 0.76 | KMT2A (0.68) | STAT3MAPTALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | STAT3 753/4885POLB 2747/4885MAPT 2968/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | STAT3 831/4885POLB 2709/4885MAPT 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.